A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Brief Description:
This study is designed to evaluate the safety and tolerability of oral Selatinib Ditosilate
Tablets, and explore the maximum tolerated dose (MTD) and dose-limiting toxicity in patients
with advanced breast cancer.